Doxorubicin induces drug efflux pumps in Candida albicans

References

• Edmond MB, Wallace SE, McClish DK, . Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 1999; 29: 239–244.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Jones RN, Messer SA, Edmond MB, Wenzel RP. National surveillance of nosocomial blood stream infection due to Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. Diagn Microbiol Infect Dis 1998; 31: 327–332.
   PubMed Web of Science ®Google Scholar
• Wisplinghoff H, Bischoff T, Tallent SM, . Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39: 309–317.
   PubMed Web of Science ®Google Scholar
• Gudlaugsson O, Gillespie S, Lee K, . Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003; 37: 1172–1177.
   PubMed Web of Science ®Google Scholar
• Viscoli C, Girmenia C, Marinus A, . Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 1999; 28: 1071–1079.
   PubMed Web of Science ®Google Scholar
• White TC, Marr KA, Bowden RA. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev 1998; 11: 382–402.
   PubMed Web of Science ®Google Scholar
• Sanglard D, Kuchler K, Ischer F, . Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob Agents Chemother 1995; 39: 2378–2386.
   PubMed Web of Science ®Google Scholar
• Sanglard D, Ischer F, Parkinson T, Falconer D, Bille J. Candida albicans mutations in the ergosterol biosynthetic pathway and resistance to several antifungal agents. Antimicrob Agents Chemother 2003; 47: 2404–2412.
   PubMed Web of Science ®Google Scholar
• Franz R, Kelly SL, Lamb DC, . Multiple molecular mechanisms contribute to a stepwise development of fluconazole resistance in clinical Candida albicans strains. Antimicrob Agents Chemother 1998; 42: 3065–3072.
   PubMed Web of Science ®Google Scholar
• Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006; 5: 219–234.
   PubMed Web of Science ®Google Scholar
• Breier A, Barancik M, Sulova Z, Uhrik B. P-glycoprotein – implications of metabolism of neoplastic cells and cancer therapy. Curr Cancer Drug Targets 2005; 5: 457–468.
   PubMed Web of Science ®Google Scholar
• Luqmani YA. Mechanisms of drug resistance in cancer chemotherapy. Med Princ Pract 2005; 14(Suppl. 1): 35–48.
   PubMedGoogle Scholar
• Chin KV, Chauhan SS, Pastan I, Gottesman MM. Regulation of mdr RNA levels in response to cytotoxic drugs in rodent cells. Cell Growth Differ 1990; 1: 361–365.
   PubMedGoogle Scholar
• Lin JH. Transporter-mediated drug interactions: clinical implications and in vitro assessment. Expert Opin Drug Metab Toxicol 2007; 3: 81–92.
   PubMed Web of Science ®Google Scholar
• Kofla G, Ruhnke M. Development of a new real-time TaqMan PCR assay for quantitative analyses of Candida albicans resistance genes expression. J Microbiol Methods 2007; 68: 178–183.
   PubMedGoogle Scholar
• Coste AT, Karababa M, Ischer F, Bille J, Sanglard D. TAC1, transcriptional activator of CDR genes, is a new transcription factor involved in the regulation of Candida albicans ABC transporters CDR1 and CDR2. Eukaryot Cell 2004; 3: 1639–1652.
   PubMed Web of Science ®Google Scholar
• Rognon B, Kozovska Z, Coste AT, Pardini G, Sanglard D. Identification of promoter elements responsible for the regulation of MDR1 from Candida albicans, a major facilitator transporter involved in azole resistance. Microbiology 2006; 152: 3701–3722.
   PubMedGoogle Scholar
• Franz R, Ruhnke M, Morschhäuser J. Molecular aspects of fluconazole resistance development in Candida albicans. Mycoses 1999; 42: 453–458.
   PubMedGoogle Scholar
• Rex JH, Pfaller MA, Walsh TJ, . Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev 2001; 14: 643–658.
   PubMed Web of Science ®Google Scholar
• Rognon B, Kozovska Z, Coste AT, Pardini G, Sanglard D. Identification of promoter elements responsible for the regulation of MDR1 from Candida albicans, a major facilitator transporter involved in azole resistance. Microbiology 2006; 152: 3701–3722.
   PubMedGoogle Scholar
• Uhl MA, Johnson AD. Development of Streptococcus thermophilus lacZ as a reporter gene for Candida albicans. Microbiology 2001; 147: 1189–1195.
   PubMedGoogle Scholar
• Coste A, Turner V, Ischer F, . A mutation in Tac1p, a transcription factor regulating CDR1 and CDR2, is coupled with loss of heterozygosity at chromosome 5 to mediate antifungal resistance in Candida albicans. Genetics 2006; 172: 2139–2156.
   PubMed Web of Science ®Google Scholar
• Pardini G, De Groot PW, Coste AT, . The CRH family coding for cell wall glycosylphosphatidylinositol proteins with a predicted transglycosidase domain affects cell wall organization and virulence of Candida albicans. J Biol Chem 2006; 281: 40399–40411.
   PubMedGoogle Scholar
• Karababa M, Coste AT, Rognon B, Bille J, Sanglard D. Comparison of gene expression profiles of Candida albicans azole-resistant clinical isolates and laboratory strains exposed to drugs inducing multidrug transporters. Antimicrob Agents Chemother 2004; 48: 3064–3079.
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungalsusceptibility testing of yeasts. Approved standard M27-A, 1997. Wayne, PA: National Committee for Clinical Laboratory Standards.
   Google Scholar
• de Micheli M, Bille J, Schueller C, Sanglard D. A common drug-responsive element mediates the upregulation of the Candida albicans ABC transporters CDR1 and CDR2, two genes involved in antifungal drug resistance. Mol Microbiol 2002; 43: 1197–1214.
   PubMed Web of Science ®Google Scholar
• Manoharlal R, Sharma M, Prasad R. Molecular determinants of transient and reversible induced up-regulation of CaCDR1 in azole susceptible clinical isolates of Candida albicans. Biosci Rep 2010 [in press]
   PubMedGoogle Scholar
• Thakur JK, Arthanari H, Yang F, . A nuclear receptor-like pathway regulating multidrug resistance in fungi. Nature 2008; 452: 604–609.
   PubMed Web of Science ®Google Scholar
• Gregori C, Schuller C, Frohner IE, Ammerer G, Kuchler K. Weak organic acids trigger conformational changes of the yeast transcription factor War1 in vivo to elicit stress adaptation. J Biol Chem 2008; 283: 25752–25764.
   PubMedGoogle Scholar
• O'Keeffe J, Kavanagh K. Adriamycin alters the expression of drug efflux pumps and confers amphotericin B tolerance in Candida albicans. Anticancer Res 2004; 24: 405–408.
   PubMedGoogle Scholar
• Henry KW, Cruz MC, Katiyar SK, Edlind TD. Antagonism of azole activity against Candida albicans following induction of multidrug resistance genes by selected antimicrobial agents. Antimicrob Agents Chemother 1999; 43: 1968–1974.
   PubMed Web of Science ®Google Scholar
• Calvet HM, Yeaman MR, Filler SG. Reversible fluconazole resistance in Candida albicans: a potential in vitro model. Antimicrob Agents Chemother 1997; 41: 535–539.
   PubMedGoogle Scholar
• Cowen LE, Sanglard D, Calabrese D, . Evolution of drug resistance in experimental populations of Candida albicans. J Bacteriol 2000; 182: 1515–1522.
   PubMed Web of Science ®Google Scholar